Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality

dc.contributor.author	Nahnsen, Sven
dc.contributor.author	Lemke, Steffen
dc.date.accessioned	2024-01-09T12:35:41Z
dc.date.available	2024-01-09T12:35:41Z
dc.date.issued	2023-06
dc.identifier.uri	http://hdl.handle.net/10900/149106
dc.language.iso	en	de_DE
dc.publisher	Elsevier	de_DE
dc.relation.uri	https://doi.org/10.1016/S0168-8278(23)01323-5	de_DE
dc.subject.ddc	004	de_DE
dc.title	Chromosome engineering and CRISPR-Cas9 viability screening reveals increased metastatic capacity targetable by patient-specific synthetic lethality	de_DE
dc.type	Article	de_DE
utue.personen.roh	Nahnsen, Sven
utue.personen.roh	Roessler, Stephanie
utue.personen.roh	Schirmacher, Peter
utue.personen.roh	Marquardt, Jens U.
utue.personen.roh	Goeppert, Benjamin
utue.personen.roh	Albrecht, Thomas
utue.personen.roh	Pusch, Stefan
utue.personen.roh	Jauch, Anna
utue.personen.roh	Eiteneuer, Eva
utue.personen.roh	Sticht, Carsten
utue.personen.roh	Ibberson, David
utue.personen.roh	Castven, Darko
utue.personen.roh	Sugiyanto, Raisatun N.
utue.personen.roh	Fritzsche, Sarah
utue.personen.roh	Lemke, Steffen
utue.personen.roh	Dreher, Emely
utue.personen.roh	Huth, Thorben
dcterms.isPartOf.ZSTitelID	POSTER PRESENTATIONS: LIVER TUMOURS EXPERIMENTAL AND PATHOPHYSIOLOGY	de_DE